Klotho Neurosciences shares fall 2.91% intraday despite positive shareholder update on partnerships and regulatory progress.

Klotho Neurosciences, Inc. declined 2.91% in intraday trading, despite the company providing a shareholder update highlighting key partnerships, regulatory progress, manufacturing advancements, and significant capital infusion. These developments are expected to accelerate the development of Klotho-based therapeutics for neurodegenerative diseases, positioning the company strongly in the growing market for ALS, Alzheimer's disease, and Parkinson's disease therapies.